12. Wenger J, Tikhomirov E, Barakamfitiye D, et al., Meningococcal vaccines in sub-Saharan Africa, Lancet, 1997;350:1709–10.
13. Slack MPE, Azzopardi HJ, Hargreaves RM, et al., Enhanced surveillance of invasive Haemophilus influenzae disease in England, 1990 to 1996: impact of conjugate vaccines, Pediatr Infect Dis J, 1998;17:S204-7.
14. Wenger JD, Epidemiology of Haemophilus influenzae type b and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada, Pediatr Infect Dis J, 1998;17:S132–6.
15. Van AL, Spanjaard L, van der EA, et al., Effect of nationwide vaccination of 3-month old infants in the Netherlands with conjugate Haemophilus influenzae type b vaccine: high efficacy and lack of herd immunity, J Pediatr, 1997;131:869–73.
16. Galiza EP, Heath PT, Conjugate vaccines : a significant milestone in vaccine development, Vaccines in Practice, 2008;1:6–7.
17. Richmond PC, Miller E, Borrow R, et al., Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory, J Infect Dis, 1999;179:1569–72.
18. Richmond P, Borrow R, Goldblatt D, et al., Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers, J Infect Dis, 2001;183:160–63.
19. Fairley CK, Begg N, Borrow R, et al., Reactogenicity and immunogenicity of conjugate meningococcal serogroup A and C vaccine in UK infants, J Infect Dis, 1996;174(6):1360–3.
20. Borrow R, Fox AJ, Richmond PC, et al., Induction of immunological memory in UK infants by a meningococcal A/C conjugate vaccine, Epidemiol Infect, 2000;124:427–32.
21. MacLennan JM, Shackley F, Heath PT, et al., Safety, immunogenicity and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants, JAMA, 2000;283:2795–801.
22. Borrow R, Goldblatt D, Andrews N et al., Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom, J Infect Dis, 2002;186:1353–7.
23. EUVac, Meningococcal vaccination (MenC) overview in European countries. Available at: www.euvac.net/graphics/
ml (accessed 3 August 2010).
24. De Greef SC, de Melker H, Spanjaard L, et al., Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands, Pediatr Infect Dis J, 2006;25:79–80.
25. Health Protection Agency, Vaccination coverage statistics for children aged up to five years in the United Kingdom: July to December 2009. Health Protection Report 26 March, 2010;4(12).
26. National Advisory Committee on Immunization (NACI), Statement on recommended use of meningococcal vaccines, Canada Communicable Disease Report, 2001;27(ACS-6):2–36.
27. National Advisory Committee on Immunization (NACI), Statement on recommended use of meningococcal vaccines, Canada Communicable Disease Report, 2007;33(ACS-11):1–14.
28. Booy R, Jelfs J, El Bashir H, et al., Impact of meningococcal
C conjugate vaccine use in Australia (Editorial), MJA, 2007;186:108–9.
29. Rosenstein NE, Perkins BA, Stephens DS, et al., The changing epidemiology of meningococcal disease in the United States, 1992–1996, J Infect Dis, 1999;180:1894–901.
30. Bilukha OO, Rosenstein N, Prevention and Control of meningococcal disease: Recommendation of the Advisory Committee on Immunization Practices (ACIP), MMWR, 2005;54(RR07):1–21.
31. Path, Dramatic fall in cases of meningitis A in three West African nations after new vaccine introduction, 2011. Available at: www.path.org/news/pr110609-menafrivac-results.php
(accessed 25 August).
32. EU-IBIS Network, Invasive Neisseria meningitidis in Europe 2006, Health Protection Agency, London 2006. Available at: www.euibis.org
(accessed 1 September 2011).
33. Campbell H, Andrews N, Borrow R, et al., Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity, Clinical & Vaccine Immunology, 2010;840–47.
34. Campbell H, Borrow R, Salisbury D, et al., Meningococcal C conjugate vaccine: the experience in England and Wales, Vaccine, 2009;27S:B20–9.
35. de Voer RM, Mollema L, Schepp RM, et al., Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine, PLoS One, 2010;13;5(8):e12144.
36. Booy R, Jelfs J, El Bashir H, et al., Impact of meningococcal C conjugate vaccine use in Australia, Med J Aust, 2007;186:108–9.
37. Cafferkey M, Murphy K, Fitzgerald M, et al., Epidemiology of meningococcal disease in Ireland: a report on laboratory confirmed cases, July 1999 to June 2000, EPI-INSIGHT, 2000;1:2–3.
38. Annual Report of the National Disease Surveillance Centre, 1999. Published by National Disease Surveillance Centre, Ireland 2000.Available at: www.ndsc.ie/hpsc/AboutHPSC/
AnnualReports/File,520,en.pdf (accessed 1 September 2011).
39. Health Protection Surveillance Centre and Meningitis Reference Laboratory, Invasive meningococcal disease and other forms of bacterial meningitis in Ireland, Quarter 4 2006, 21 March 2007. Available at: www.ndsc.ie/hpsc/A-Z/
VaccinePreventable/BacterialMeningitis/Publications/ 2006Reports/File,2274,en.pdf (accessed 1 September 2011).
40. Martin C, Maiden J, Ibarz-Pavón AB, et al., Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity, J Infect Dis, 2008;197:737–43.
41. Trotter CL, Edmunds WJ, The cost-effectiveness of the meningococcal group C conjugate vaccination campaign in England and Wales, BMJ, 2002;324:809.
42. Trotter C, Andrews N, Kaczmarski E, et al., Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction, Lancet, 2004;354:365–7.
43. Snape MD, Kelly DF, Lewis S, et al., Seroprotection against serogroup C meningococcal disease in adolescents in the UK: observational study, BMJ, 2008;336:1487–91.
44. Larrauri A, Cano R, García M, et al., Impact and effectiveness
of meningococcal C conjugate vaccine following its introduction in Spain, Vaccine, 2005;23:4097–100.
45. Borrow R, Andrews N, Findlow H, et al., Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine at 12 to 15 months of age in healthy UK infants primed with two doses of one of three monovalent meningococcal serogroup C vaccines, Clin Vaccine Immunol, 2010;17:154–9.
46. Maiden MCJ, Spratt BG, Meningococcal conjugate vaccines: new opportunities and new challenges, Lancet, 1999;354:615–6.
47. Southern J, Gelb D, Andrews N, et al., Reactogenicity of meningococcal C conjugate vaccines when administered at the same time as, a month prior to or after, tetanus and diphtheria booster vaccinations, Hum Vaccin, 2006;2:237–42.
48. Medicines Control Agency, Report of the Committee on Safety of Medicines Expert Working Group on Meningococcal Group C conjugate vaccines, 23 May 2002. Available at: www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsan
drecalls/Safetywarningsandmessagesformedicines/ CON2015729 (accessed 1 September 2011).
49. Abeyagunawardena AS, Goldblatt D, Andrews N, et al., Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome, Lancet, 2003;362:449–50.
50. Taylor B, Andrews N, Stowe J, et al., No increased risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome, Arch Dis Child, 2007;92:887–9.
51. Andrews N, Stowe J, Miller E, et al., Post-licensure safety of the meningococcal group C conjugate vaccine, Hum Vaccin, 2007;3:59–63.
52. Ward KN, Bryant NJ, Andrews NJ, et al., Risk of serious neurologic disease after immunization of young children in Britain and Ireland, Pediatrics, 2007;120:314–21.
53. Stowe J, Andrews N, Taylor B, et al., No evidence of an increase of bacterial and viral infections following measles, mumps and rubella vaccine, Vaccine, 2009;25;27(9):1422–5.
54. Snape MD, Kelly DF, Lewis S, et al., Seroprotection against serogroup C meningococcal disease in adolescents in the UK: observational study, BMJ, 2008;336:1487–91.
55. Thomas HL, Andrews N, Trotter C, et al., Meningococcal C booster not recommended by evidence, BMJ, 2008;337:a1139.
56. Trotter CL, McVernon J, Ramsay ME, et al., Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae, Vaccine, 2008;26:4434–5.
57. Southern J, Crowley-Luke A, Borrow R, et al., Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine, Vaccine, 2006;24:215–9.
58. Southern J, Borrow R, Andrews N, et al., Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with a 7-valent pneumococcal conjugate vaccine and a combination DTaP5/Hib/IPV vaccine in healthy UK infants, Clin Vaccine Immunol, 2009;16:194–9.
EUROPEAN INFECTIOUS DISEASE
| Page 2
| Page 3
| Page 4
| Page 5
| Page 6
| Page 7
| Page 8
| Page 9
| Page 10
| Page 11
| Page 12
| Page 13
| Page 14
| Page 15
| Page 16
| Page 17
| Page 18
| Page 19
| Page 20
| Page 21
| Page 22
| Page 23
| Page 24
| Page 25
| Page 26
| Page 27
| Page 28
| Page 29
| Page 30
| Page 31
| Page 32
| Page 33
| Page 34
| Page 35
| Page 36
| Page 37
| Page 38
| Page 39
| Page 40
| Page 41
| Page 42
| Page 43
| Page 44
| Page 45
| Page 46
| Page 47
| Page 48
| Page 49
| Page 50
| Page 51
| Page 52
| Page 53
| Page 54
| Page 55
| Page 56
| Page 57
| Page 58
| Page 59
| Page 60
| Page 61
| Page 62
| Page 63
| Page 64
| Page 65
| Page 66
| Page 67
| Page 68
| Page 69
| Page 70
| Page 71
| Page 72
| Page 73
| Page 74
| Page 75
| Page 76
| Page 77
| Page 78
| Page 79
| Page 80
| Page 81
| Page 82
| Page 83
| Page 84
| Page 85
| Page 86
| Page 87
| Page 88
| Page 89
| Page 90
| Page 91
| Page 92